(Reuters) -Eli Lilly said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of body weight in a late-stage trial, after recent data from another study of the drug in patients without diabetes sent company shares tumbling.

Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting.’